Mode
Text Size
Log in / Sign up
N/A N=104 Randomized Double-blind Supportive Care

Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers

Myopia · Astigmatism · Refractive Error

Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Nov 2012
Primary outcome: Primary: Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14 — 87.40; 88.79; 81.75; 83.18 Units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
OPTI-FREE RepleniSH multipurpose solution (Device); ReNu Biotrue multipurpose solution (Device); Silicone hydrogel contact lenses (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Alcon Research
Primary completion
Nov 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline (Day 0) in Ocular Comfort Rating at Day 14
87.40; 88.79; 81.75; 83.18; -5.65; -5.61

Summary

The purpose of this study was to assess the comfort of OPTI-FREE RepleniSH in soft contact lens wearers.

Eligibility Criteria

Inclusion Criteria

  • Currently wearing silicone hydrogel contact lenses on a daily wear basis;
  • Currently using OPTI-FREE RepleniSH contact lens solution;
  • Generally healthy;
  • Normal ocular health;
  • Willing to follow study procedures and visit schedule;
  • Sign Informed Consent and privacy document;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Use of additional lens cleaners;
  • Known sensitivities to any ingredient in either test article;
  • Systemic or ocular disease or disorder that would negatively affect the conduct or outcome of the study;
  • History of ocular surgery/trauma within the last 6 months;
  • Any topical ocular or systemic antibiotics within 7 days of enrollment continuing throughout the study;
  • Participation in any other ophthalmic drug or device clinical trial within 30 days of enrollent;
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01211535). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search